Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

Shigehisa Kubota; Susumu Kageyama; Masayuki Nagasawa; Akinori Wada; Ryo Ikari; Keiji Tomita; Tetsuya Yoshida; Mitsuhiro Narita; Akihiro Kawauchi

doi:10.12659/AJCR.930989

05 July 2021 : Case report Japan

Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Shigehisa Kubota^1ABCDEF, Susumu Kageyama^1ADE*, Masayuki Nagasawa^1CF, Akinori Wada^1BC, Ryo Ikari^1BD, Keiji Tomita^1DF, Tetsuya Yoshida^1ABF, Mitsuhiro Narita^1ADF, Akihiro Kawauchi^1ADE

DOI: 10.12659/AJCR.930989

Am J Case Rep 2021; 22:e930989

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 1. Status of bone metastasis by scintigraphy. (A) Multiple metastases to ribs, vertebrae and pelvic bone at the time of prostate cancer diagnosis. (B) Jaw osteonecrosis (black arrowhead) induced by denosumab occurring after the 26th cycle of cabazitaxel. (C) Abnormal uptake in the right femoral head (white arrowhead) and right sixth rib (black arrow) caused by idiopathic femoral head necrosis and traumatic rib injury after the 52nd cycle of cabazitaxel.

Back to the Article

Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report

Your Privacy